nifedipine has been researched along with omeprazole in 35 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (2.86) | 18.7374 |
1990's | 7 (20.00) | 18.2507 |
2000's | 12 (34.29) | 29.6817 |
2010's | 12 (34.29) | 24.3611 |
2020's | 3 (8.57) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Gao, F; Lombardo, F; Shalaeva, MY; Tupper, KA | 1 |
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Pratim Roy, P; Roy, K | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Burburan, PJ; Matubia, VN; Parkin, DW; Ramcharan, SS; Rosario, I; Shea, TA; Stockman, BJ | 1 |
Bharate, SS; Vishwakarma, RA | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
Breimer, DD; Danhof, M; Jansen, JB; Lamers, CB; Soons, PA; van Brummelen, P; van den Berg, G | 1 |
Banerjee, RK; Bhattacharjee, M; Bose, AK | 1 |
Grönniger, J; Hillemanns, A; Oglodek, C; Reinbold, WD | 1 |
Bliesath, H; Hartmann, M; Huber, R; Radtke, HW; Steinijans, VW; Wurst, W; Zech, K | 1 |
Bliesath, H; Huber, R; Koch, HJ; Kunz, K; Steinijans, VW; Wurst, W | 2 |
Ishizaki, T; Zhao, XJ | 1 |
Shimada, T; Yamazaki, H | 1 |
Karlstadt, RG; Walker, K | 1 |
Marks, B; Raucy, J; Trubetskoy, O; Yueh, MF; Zielinski, T | 1 |
Achem, SR | 1 |
Bowen, CL; Evans, CA; Hemberger, MD; Kehler, JR | 1 |
Babiskin, A; Le Merdy, M; Lee, SC; Ni, Z; Sun, D; Tan, ML; Zhao, L | 1 |
Feng, K; Kinjo, M; Lionberger, R; Sun, D; Tan, ML; Wang, H; Xu, M; Zhao, L | 1 |
4 review(s) available for nifedipine and omeprazole
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
Lack of pantoprazole drug interactions in man.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Antipyrine; Benzimidazoles; Contraceptives, Oral, Hormonal; Cross-Over Studies; Cytochrome P-450 Enzyme System; Diazepam; Digoxin; Drug Interactions; Female; Humans; Liver; Longitudinal Studies; Male; Nifedipine; Omeprazole; Pantoprazole; Phenytoin; Proton Pump Inhibitors; Sulfoxides; Theophylline; Tissue Distribution; Warfarin | 1994 |
Treatment of non-cardiac chest pain.
Topics: Anti-Ulcer Agents; Botulinum Toxins, Type A; Calcium Channel Blockers; Chest Pain; Diltiazem; Enzyme Inhibitors; Esophageal Motility Disorders; Esophageal Spasm, Diffuse; Gastroesophageal Reflux; Hyperalgesia; Neuromuscular Agents; Nifedipine; Nitrates; Omeprazole; Ranitidine; Transcutaneous Electric Nerve Stimulation | 2008 |
4 trial(s) available for nifedipine and omeprazole
Article | Year |
---|---|
Influence of single- and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects.
Topics: Adult; Analysis of Variance; Blood Pressure; Double-Blind Method; Drug Interactions; Gastric Acidity Determination; Heart Rate; Humans; Male; Nifedipine; Omeprazole; Reference Values | 1992 |
Lack of pantoprazole drug interactions in man.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Absorption; Antipyrine; Benzimidazoles; Contraceptives, Oral, Hormonal; Cross-Over Studies; Cytochrome P-450 Enzyme System; Diazepam; Digoxin; Drug Interactions; Female; Humans; Liver; Longitudinal Studies; Male; Nifedipine; Omeprazole; Pantoprazole; Phenytoin; Proton Pump Inhibitors; Sulfoxides; Theophylline; Tissue Distribution; Warfarin | 1994 |
Pantoprazole does not interact with nifedipine in man under steady-state conditions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Anticonvulsants; Area Under Curve; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Drug Interactions; Electrocardiography; Enzyme Inhibitors; Female; Half-Life; Heart Rate; Humans; Male; Nifedipine; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 1996 |
Pantoprazole does not interact with nifedipine in man under steady-state conditions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazoles; Calcium Channel Blockers; Cross-Over Studies; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Female; Hemodynamics; Humans; Liver; Male; Nifedipine; Omeprazole; Pantoprazole; Sulfoxides | 1996 |
28 other study(ies) available for nifedipine and omeprazole
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
Topics: 1-Octanol; Chromatography, High Pressure Liquid; Pharmaceutical Preparations; Solubility; Water | 2001 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
Topics: Algorithms; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Inhibitors; Factor Analysis, Statistical; Least-Squares Analysis; Linear Models; Models, Molecular; Neural Networks, Computer; Quantitative Structure-Activity Relationship; Reproducibility of Results | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Molecular Structure; N-Glycosyl Hydrolases; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Rabeprazole; Structure-Activity Relationship; Trichomonas vaginalis | 2014 |
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Topics: Drug Discovery; Pharmaceutical Preparations; Solubility; Thermodynamics | 2015 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Histamine H2-receptor mediated stimulation of gastric acid secretion by mercaptomethylimidazole.
Topics: Animals; Cimetidine; Gastric Acid; Male; Methimazole; Mice; Mice, Inbred BALB C; Nifedipine; Omeprazole; Parietal Cells, Gastric; Potassium; Proton-Translocating ATPases; Pylorus; Receptors, Histamine H2; Sodium; Verapamil | 1989 |
[Leiomyomatosis of the esophagus].
Topics: Anti-Ulcer Agents; Biopsy; Cisapride; Combined Modality Therapy; Deglutition Disorders; Esophageal Neoplasms; Esophagus; Follow-Up Studies; Humans; Leiomyomatosis; Magnetic Resonance Imaging; Male; Middle Aged; Nifedipine; Omeprazole; Pathology; Piperidines; Tomography, X-Ray Computed | 1994 |
Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes.
Topics: Anti-Infective Agents; Antimalarials; Chromatography; Cytochrome P-450 Enzyme System; Doxycycline; Drug Interactions; Erythromycin; Humans; Hydroxylation; Ketoconazole; Microsomes, Liver; Nifedipine; Omeprazole; Primaquine; Quinine; Tetracycline; Troleandomycin | 1997 |
Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes.
Topics: Arachidonic Acid; Aryl Hydrocarbon Hydroxylases; Cholecalciferol; Coumarins; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2A6; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Ethanolamines; Humans; Isoenzymes; Lauric Acids; Microsomes, Liver; Mixed Function Oxygenases; Nifedipine; Omeprazole; Oxidation-Reduction; Oxidoreductases, N-Demethylating; Paclitaxel; Prostaglandins; Recombinant Proteins; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Theophylline; Tretinoin; Warfarin; Xenobiotics | 1999 |
Update on prescribing information for pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Digoxin; Drug Interactions; Esophagitis; Humans; Nifedipine; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Sulfoxides | 2003 |
A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Chromans; Clotrimazole; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Dimethyl Sulfoxide; Enhancer Elements, Genetic; Enzyme Induction; Genes, Reporter; Genes, Synthetic; Humans; Ketoconazole; Liver Neoplasms; Lovastatin; Luciferases; Mifepristone; Neoplasm Proteins; Nifedipine; Omeprazole; Paclitaxel; Phenytoin; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Recombinant Fusion Proteins; Rifampin; Thiazolidinediones; Transcription, Genetic; Troglitazone; Troleandomycin | 2005 |
Utility of dried blood spot sampling and storage for increased stability of photosensitive compounds.
Topics: Animals; Blood Chemical Analysis; Blood Specimen Collection; Desiccation; Drug Stability; Light; Nifedipine; Omeprazole; Photochemical Processes; Rats; Solvents | 2010 |
Physiologically Based Pharmacokinetic Modeling Approach to Identify the Drug-Drug Interaction Mechanism of Nifedipine and a Proton Pump Inhibitor, Omeprazole.
Topics: Calcium Channel Blockers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Models, Biological; Nifedipine; Omeprazole; Proton Pump Inhibitors | 2021 |
Effect of Omeprazole Administration on the Pharmacokinetics of Oral Extended-Release Nifedipine in Healthy Subjects.
Topics: Administration, Oral; Area Under Curve; Biological Availability; Cross-Over Studies; Healthy Volunteers; Humans; Nifedipine; Omeprazole; Tablets | 2023 |